Register studies with excellent coverage and deep data are possible in Finland Nationwide noninterventional, retrospective chart review explored real-life characteristics and outcomes of patients with Crohn’s disease in Finland. Research was published in the Scandinavian Journal of Gastroenterology: link.
Conditional reimbursement context: An economic evaluation including a risk-sharing scheme A hybrid-modeling study that evaluated the clinical outcomes, cost-effectiveness, and budget impact of biologic rheumatoid arthritis drugs as a treatment mix and individually for biologic-naïve patients in Finland has been recently published. The assessment includes also certolizumab pegol with and without a hypothetical efficacy-based risk-sharing […]
The hidden costs of impairments in working ability and functional capacity among Finnish patients with inflammatory bowel diseases and rheumatoid arthritis were assessed in a collaborative effort by ESiOR Oy, Abbvie Oy, The Crohn and Colitis association (Crohn ja Colitis ry), Confederation of Finnish Industries (EK), The Finnish Medical Association, The Finnish Rheumatism Association, SITRA, […]
Multiple sclerosis (MS) progression and the cost-effectiveness analysis of first line disease modifying MS treatments (DMT) in Finland ESiOR studied relapsing-remitting MS (RRMS) progression and cost of relapses based on visualization and analysis of Finnish patient-level MS register real-world (RWD) data. The real-world treatment path evidence (RWE) and costs were synthesized with e.g. DMT efficacy […]
Many patients with major depressive disorder (MDD) do not have adequate response to the first medical treatment or have adverse effects that lead to treatment discontinuation and change of medication. MDD causes major quality of life losses and it is among the leading causes of early retirement. As such, the assessment of cost-effectiveness of MDD […]
A large proportion of patients with atrial fibrillation (AF) do not attain the treatment targets with traditional warfarin treatment. As a result, they remain at increased risk for AF-related events (stroke, hemorrhage) and other warfarin treatment associated adversities. Regardless of treatment balance, warfarin treatment causes significant monitoring costs making it worthwhile to study alternative treatments. […]
Cost-effectiveness of apixaban and warfarin in the prevention of thromboembolic complications among atrial fibrillation patients.
Most health economists have probably faced a situation where ICER, CEEF, CEAF, EVPI or some other complicated cost-utility analysis outcome do not alone make the case in practical value demonstration and decision making for the clinics. In many cases, elaboration of cost-effectiveness towards clinical outcomes, clinical value analysis and clinical cost-benefit analysis is needed. In […]
In our recent publication, we analysed the cost-effectiveness of dabigatran in the prevention of stroke for patients with atrial fibrillation. The published analyses are based on a prior, unpublished health economic assessment that has been evaluated by FIMEA in its pilot project. The health care costs and drug prices were updated to year 2011 level […]
Our recent publication assessed the real-life use of extended and immediate release quetiapine in patients with schizophrenia spectrum disorders and bipolar disorder in Lappeenranta. Much to the surprise of the study group, the use of extended and immediate release quetiapine differed considerably in real life. Immediate release quetiapine was used in significantly lower doses when […]